Ranbaxy recalls drug in Canada; Pfizer U.K. facility demolished;

> Ranbaxy Pharmaceuticals Canada, a Ranbaxy subsidiary, has recalled one batch of RAN-gabapentin, a medication used to treat epilepsy, because of cross-contamination during the manufacturing process with Etodolac, a nonsteroidal anti-inflammatory drug. Report

> India will toughen up the rules that drugmakers there must follow about the authenticity of data used to support drugs manufactured there or imported for use there. Report

> Recipharm has made a $2 million equity investment in Synthonics, which allows Synthonics access to Recipharm's drug development and manufacturing expertise in exchange for royalties on some of its APIs. Release

> A former Pfizer ($PFE) distribution center in Hampshire, U.K., will be demolished to make way for a new development. Report

> American Health Packaging in Columbus, Ohio, is recalling 2,284 cartons of benzonatate capsules after receiving reports that they were wet. Report

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.